Literature DB >> 6734708

Individualizing theophylline dosage: evaluation of a single-point maintenance dose prediction method.

J H Wilkens, H Neuenkirchen, G W Sybrecht, M Oellerich.   

Abstract

A dosage prediction method to estimate theophylline clearance and dose requirement was evaluated in 22 outpatients with partly reversible obstructive airways disease. The steady state theophylline dose required to achieve a target concentration (Css) was predicted using a single serum theophylline determination 8 h after a single oral test dose. In 17 nonsmoking patients a mean absolute deviation of 8.2% (range 0.0-21.7%) between predicted and observed Css was found, and in 5 smoking patients the mean deviation was 34.0% (range 2.2-53.8%). In 17 healthy smokers the single-point method was found to predict theophylline clearance at a sampling time of 8 h with a prediction error of 11.3 (range 0.8-25.3%) compared to the clearance determination using the area under the curve. In addition, a numerical simulation program to assess the influence of absorption, elimination and sampling time on predictive accuracy showed that the method could be successfully applied to a patient population with elimination rate constants between 0.07 1/h and 0.25 1/h, allowing a mean prediction error of 15%.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734708     DOI: 10.1007/BF00542147

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  37 in total

1.  Drug therapy: patient compliance.

Authors:  B Blackwell
Journal:  N Engl J Med       Date:  1973-08-02       Impact factor: 91.245

2.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

3.  Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.

Authors:  Y Horai; T Ishizaki; T Sasaki; K Chiba; T Suganuma; H Echizen; A Ohnishi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Method for the rapid estimation of the total body drug clearance and adjustment of dosage regimens in patients during a constant-rate intravenous infusion.

Authors:  W L Chiou; M A Gadalla; G W Peng
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

5.  Single-point prediction methods: a critical review.

Authors:  J R Koup
Journal:  Drug Intell Clin Pharm       Date:  1982-11

6.  Influence of methylxanthine-containing foods on theophylline metabolism and kinetics.

Authors:  T J Monks; J Caldwell; R L Smith
Journal:  Clin Pharmacol Ther       Date:  1979-10       Impact factor: 6.875

7.  Estimation of kinetic parameters from a two-point determination of the drug cumulation factor.

Authors:  T D Bjornsson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

8.  Evaluation of the "condition correction factor" method of estimating theophylline clearance.

Authors:  V P Gotz; W L Russell; L M Lopez
Journal:  Ther Drug Monit       Date:  1983       Impact factor: 3.681

9.  The effects of erythromycin on the absorption and disposition of kinetics of theophylline.

Authors:  T A Branigan; R A Robbins; W J Cady; J G Nickols; C T Ueda
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  [Theophylline therapy in obstructive respiratory diseases. 1. Bioavailability and pharmacokinetics of various theophylline preparations (author's transl)].

Authors:  S Wemhöner; M Oellerich; G Sybrecht
Journal:  Prax Klin Pneumol       Date:  1981-01
View more
  2 in total

1.  A minimax approach to the single-point method of drug dosing.

Authors:  M M Bahn; E M Landaw
Journal:  J Pharmacokinet Biopharm       Date:  1987-06

Review 2.  An updated comparison of drug dosing methods. Part II: Theophylline.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.